Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline and Pozen's painkiller Trexima can protect against multiple migraine attacks over 24 hours, according to the results of a new study.
Subscribe to our email newsletter
New data from more than 1,100 patients show that the investigational migraine therapy, when taken early, produced pain-free results at two and four hours, as well as a sustained pain-free response 2-24 hours, across individual patients' multiple migraine attacks, the companies said. Furthermore, nearly one third of all patients were pain-free at two hours.
Trexima, the proposed brand name for a single tablet containing sumatriptan 85mg formulated with RT Technology and naproxen sodium 500mg, is currently under review by the FDA for the acute treatment of migraines in adults.
The drug has been developed under an agreement between GSK and Pozen. GSK is responsible for formulation development, manufacturing and commercialization, while Pozen is responsible for the pre-clinical, clinical, and regulatory development activities for Trexima.